PubRank

T G Theander

Author PubWeight™ 124.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000 3.74
2 A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol 1998 2.94
3 Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry 1999 2.87
4 Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Am J Trop Med Hyg 1996 2.72
5 Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999 2.16
6 Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett 2000 1.89
7 The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 1999 1.77
8 Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000 1.76
9 Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun 2001 1.69
10 Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria. Immunology 1993 1.64
11 Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect Immun 1999 1.59
12 Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity. Immunology 1994 1.55
13 The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. Trans R Soc Trop Med Hyg 2001 1.53
14 Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 1993 1.50
15 Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology 1998 1.48
16 Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun 1997 1.45
17 Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria. Eur J Immunol 1991 1.44
18 Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun 2001 1.44
19 Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1994 1.42
20 Random amplified polymorphic DNA for the differentiation of Leishmania donovani isolates from Sudan. Trans R Soc Trop Med Hyg 1996 1.41
21 High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998 1.40
22 A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. J Immunol Methods 1993 1.29
23 Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett 1993 1.25
24 Chronic Plasmodium falciparum infections in an area of low intensity malaria transmission in the Sudan. Parasitology 2000 1.25
25 Eleven years of malaria surveillance in a Sudanese village highlights unexpected variation in individual disease susceptibility and outbreak severity. Parasitology 2004 1.23
26 Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by Plasmodium falciparum. Parasitology 1999 1.21
27 The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis 1997 1.18
28 The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Ann Trop Med Parasitol 2005 1.17
29 Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob Agents Chemother 2001 1.17
30 Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother 1994 1.16
31 Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994 1.16
32 Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiol Immunol 1991 1.15
33 Seasonal variation in agglutination of Plasmodium falciparum-infected erythrocytes. Am J Trop Med Hyg 1998 1.15
34 Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother 1993 1.14
35 Suppression of parasite-specific response in Plasmodium falciparum malaria. A longitudinal study of blood mononuclear cell proliferation and subset composition. Scand J Immunol 1986 1.14
36 Recognition of Leishmania antigens by T lymphocytes from nonexposed individuals. Infect Immun 1992 1.13
37 Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol 1999 1.11
38 Lymphocyte response to purified Plasmodium falciparum antigens during and after malaria. Acta Trop 1986 1.11
39 Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother 1994 1.11
40 The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today 1996 1.10
41 Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999 1.10
42 Soluble Plasmodium falciparum antigens contain carbohydrate moieties important for immune reactivity. J Clin Microbiol 1987 1.09
43 Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res 1994 1.09
44 Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol 1994 1.08
45 Clinical pattern of severe Plasmodium falciparum malaria in Sudan in an area characterized by seasonal and unstable malaria transmission. Trans R Soc Trop Med Hyg 2005 1.07
46 Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Trans R Soc Trop Med Hyg 1996 1.07
47 High proportion of subclinical Plasmodium falciparum infections in an area of seasonal and unstable malaria in Sudan. Am J Trop Med Hyg 1995 1.04
48 Specific T-cell recognition of the merozoite proteins rhoptry-associated protein 1 and erythrocyte-binding antigen 1 of Plasmodium falciparum. Infect Immun 1993 1.04
49 Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol 1999 1.03
50 A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Infect Immun 1999 1.03
51 Diagnosis of visceral leishmaniasis by the polymerase chain reaction using blood, bone marrow and lymph node samples from patients from the Sudan. Trop Med Int Health 1997 1.02
52 Proliferation induced by Plasmodium falciparum antigen and interleukin-2 production by lymphocytes isolated from malaria-immune individuals. Infect Immun 1986 1.02
53 Specific proliferative response of human lymphocytes to purified soluble antigens from Plasmodium falciparum in vitro cultures and to antigens from malaria patients' sera. Clin Exp Immunol 1985 1.01
54 Activation of human T lymphocytes by Leishmania lipophosphoglycan. Scand J Immunol 1991 1.01
55 Cell-mediated immune responses to Plasmodium falciparum purified soluble antigens in sickle-cell trait subjects. Immunol Lett 1990 1.00
56 Cellular and humoral immune responses in a population from the Baringo District, Kenya to Leishmania promastigote lipophosphoglycan. Am J Trop Med Hyg 1992 1.00
57 T-cell response in human leishmaniasis. Immunol Lett 1999 1.00
58 Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 1999 1.00
59 The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 2000 0.99
60 Antibody responses to Rhoptry-Associated Protein-1 (RAP-1) of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Parasite Immunol 1997 0.98
61 Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Trans R Soc Trop Med Hyg 1999 0.96
62 Increased plasma levels of soluble IL-2R are associated with severe Plasmodium falciparum malaria. Clin Exp Immunol 1994 0.95
63 Antibody reactivity to conserved linear epitopes of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Immunol Lett 1998 0.94
64 Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol 1998 0.94
65 The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role? Med Hypotheses 2006 0.93
66 Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections. Clin Exp Immunol 1995 0.92
67 The gamma/delta T-cell response to Plasmodium falciparum malaria in a population in which malaria is endemic. Infect Immun 1996 0.90
68 Antigen-presenting cells in human cutaneous leishmaniasis due to Leishmania major. Clin Exp Immunol 1995 0.90
69 Insecticide-treated bed nets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clin Diagn Lab Immunol 2001 0.90
70 Functional and phenotypic changes in human lymphocytes after coincubation with Leishmania donovani in vitro. Infect Immun 1990 0.89
71 Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani(1). Biochim Biophys Acta 2001 0.89
72 Interleukin-4 and interferon-gamma production by Leishmania stimulated peripheral blood mononuclear cells from nonexposed individuals. Scand J Immunol 1995 0.89
73 The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. FEMS Immunol Med Microbiol 1998 0.88
74 Seasonal changes in cell mediated immune responses to soluble Plasmodium falciparum antigens in children with haemoglobin AA and haemoglobin AS. Trans R Soc Trop Med Hyg 1992 0.88
75 The pathology of cutaneous leishmaniasis due to Leishmania major in Sudan. Am J Trop Med Hyg 1995 0.88
76 Modulation of the cellular immune response during Plasmodium falciparum infections in sickle cell trait individuals. Clin Exp Immunol 1992 0.87
77 Molecular characterization of a Leishmania donovanii cDNA clone with similarity to human 20S proteasome a-type subunit. Biochim Biophys Acta 2000 0.86
78 Low parasite specific T cell response in clinically immune individuals with low grade Plasmodium falciparum parasitaemia. Trans R Soc Trop Med Hyg 1986 0.86
79 The major surface glycoprotein (gp63) from Leishmania major and Leishmania donovani cleaves CD4 molecules on human T cells. J Immunol 1994 0.86
80 Diversity among Leishmania isolates from the Sudan: isoenzyme homogeneity of L. donovani versus heterogeneity of L. major. Trans R Soc Trop Med Hyg 1995 0.85
81 Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 1993 0.85
82 Effect of pyrimethamine and sulphadoxine on human lymphocyte proliferation. Trans R Soc Trop Med Hyg 1986 0.84
83 The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine 2011 0.84
84 Cell-mediated immune responses to soluble Plasmodium falciparum antigens in residents from an area of unstable malaria transmission in the Sudan. APMIS 1990 0.83
85 Selective modulation of the CD4 molecular complex by Pseudomonas aeruginosa alkaline protease and elastase. Scand J Immunol 1987 0.83
86 Effects of chloroquine, mefloquine and quinine on natural killer cell activity in vitro. An analysis of the inhibitory mechanism. Allergy 1986 0.82
87 Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. Immunol Lett 1993 0.82
88 Serodiagnosis of cutaneous leishmaniasis: assessment of an enzyme-linked immunosorbent assay using a peptide sequence from gene B protein. Am J Trop Med Hyg 1996 0.82
89 Antiprotozoal properties of 16,17-dihydrobrachycalyxolide from Vernonia brachycalyx. Planta Med 1998 0.81
90 The relation between T-cell expression of LFA-1 and immunological memory. Immunology 1993 0.81
91 Interferon-gamma and interleukin-4 production by human T cells recognizing Leishmania donovani antigens separated by SDS-PAGE. APMIS 1995 0.81
92 Lymphoproliferative responses to Plasmodium falciparum antigens in children with and without the sickle cell trait. Scand J Immunol 1991 0.81
93 Recombinant human tumour necrosis factor is not inhibitory to Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1988 0.81
94 Two new antiprotozoal 5-methylcoumarins from Vernonia brachycalyx. J Nat Prod 1997 0.80
95 The efficacy of artemether in the treatment of Plasmodium falciparum malaria in Sudan. Trans R Soc Trop Med Hyg 1994 0.79
96 Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. Tanzan J Health Res 2008 0.79
97 High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Trop 2000 0.79
98 Soluble haemoglobin is a marker of recent Plasmodium falciparum infections. Immunol Lett 1997 0.79
99 Pseudomonas aeruginosa septicaemia in a patient with severe Plasmodium falciparum. Trans R Soc Trop Med Hyg 1987 0.79
100 Suppression of blood monocyte and neutrophil chemotaxis in acute human malaria. Parasite Immunol 1986 0.78
101 Dichotomy in the human CD4+ T-cell response to Leishmania parasites. APMIS 1994 0.78
102 Determinants of variant surface antigen antibody response in severe Plasmodium falciparum malaria in an area of low and unstable malaria transmission. Scand J Immunol 2006 0.77
103 Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. Int J Immunopharmacol 1987 0.77
104 Differential T-cell expression of LFA-1 in residents from Africa and Denmark. Description of the phenomenon and its possible basis. Immunol Lett 1994 0.77
105 In vitro effect of chloroquine, mefloquine and quinine on human lymphocyte proliferative responses to malaria antigens and other antigens/mitogens. Trop Med Parasitol 1986 0.77
106 An antileishmanial chalcone from Chinese licorice roots. Planta Med 1994 0.76
107 Th1-like human T-cell clones recognizing Leishmania gp63 inhibit Leishmania major in human macrophages. Scand J Immunol 1994 0.76
108 Depressed natural killer cell activity in acute myocardial infarction. Clin Exp Immunol 1987 0.76
109 Kinetics of human T-cell expression of LFA-1, IL-2 receptor, and ICAM-1 following antigenic stimulation in vitro. J Clin Lab Immunol 1993 0.76
110 Blood monocyte oxidative burst activity in acute P. falciparum malaria. APMIS 1989 0.76
111 Cloning, expression and antigenicity of the L. donovani reductase. APMIS 2001 0.76
112 In vitro effects of artesunate and other antimalarial agents on the function of human lymphocytes and neutrophils. Transplant Proc 1994 0.75
113 The use of nominal group technique in identifying community health priorities in Moshi rural district, northern Tanzania. Tanzan Health Res Bull 2005 0.75
114 Seasonal changes in human immune responses to malaria. Parasitol Today 1993 0.75
115 Modification of T-cell antigenic properties of tetanus toxoid by SDS-PAGE separation. Implications for T-cell blotting. J Immunoassay 1997 0.75
116 [Human infection immunology. Basic scientific findings and clinical consequences]. Ugeskr Laeger 2000 0.75
117 Identification and localization of a soluble antigen, Ag2, of 136 kDa from Plasmodium falciparum in vitro cultures. APMIS 1991 0.75
118 Biochemical characterization, localization and immunostimulating properties of a soluble glycoprotein, Ag1, isolated from in vitro cultures of Plasmodium falciparum. Parasitol Res 1990 0.75
119 Isolation and characterization of a soluble antigen complex of Plasmodium falciparum with pyrogenic properties. APMIS 1991 0.75
120 Pattern of pre-existing IgG subclass responses to a panel of asexual stage malaria antigens reported during the lengthy dry season in Daraweesh, Sudan. Scand J Immunol 2011 0.75
121 Antibody reactivities to glutamate-rich peptides of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. APMIS 1996 0.75
122 T-cell responses in malaria. APMIS 1992 0.75
123 Effect of praziquantel on human lymphocyte proliferation in vitro. Eur J Clin Pharmacol 1984 0.75
124 [Leishmaniasis]. Ugeskr Laeger 2000 0.75